Table 3. IC50 valuesa (μM) of compounds 1-8 against carcinoma and normal tissue cell lines.
Carcinoma cell lines | Normal tissue cell lines | ||||
---|---|---|---|---|---|
No. | U2OS | SW620 | ES-2 | Lo2 | Vero |
1 | 111.40±1.29 | 45.02±1.23 | 55.50±1.08 | 150.30±1.09 | >300 |
2 | 54.24±1.10 | 103.80±1.07 | 76.78±1.09 | >300 | 260.40±1.16 |
3 | 73.19±1.24 | 70.93±1.08 | 90.58±1.12 | >300 | >300 |
4 | 66.44±1.11 | 56.46±1.15 | 64.24±1.28 | 279.10±2.17 | >300 |
5 | 64.40±1.08 | 61.80±±1.06 | 80.13±3.56 | >300 | >300 |
6 | 57.79±1.07 | 53.72±1.06 | 37.26±3.56 | >300 | >300 |
7 | 96.30±1.13 | 100.70±1.07 | 74.45±1.17 | >300 | >300 |
8 | 95.36±1.05 | 55.21±1.16 | 60.88±1.34 | >300 | >300 |
(S)-Cb | 32.28±1.28 | 17.50±1.11 | 9.09±1.06 | 26.01±1.20 | 16.69±1.15 |
a IC50 values of the isolated compounds were obtained from the mean OD values of the triplicate tests versus the drug concentration curves.
b (S)-C represents (S)-crizotinib, which was used as positive control.